Literature DB >> 3466164

Human class II (pi) alcohol dehydrogenase has a redox-specific function in norepinephrine metabolism.

G Mårdh, A L Dingley, D S Auld, B L Vallee.   

Abstract

Studies of the function of human alcohol dehydrogenase (ADH) have revealed substrates that are virtually unique for class II ADH (pi ADH). It catalyzes the formation of the intermediary glycols of norepinephrine metabolism, 3,4-dihydroxyphenylglycol and 4-hydroxy-3-methoxyphenylglycol, from the corresponding aldehydes 3,4-dihydroxymandelaldehyde and 4-hydroxy-3-methoxymandelaldehyde with Km values of 55 and 120 microM and kcat/Km ratios of 14,000 and 17,000 mM-1 X min-1; these are from 60- to 210-fold higher than those obtained with class I ADH isozymes. The catalytic preference of class II ADH also extends to benzaldehydes. The kcat/Km values for the reduction of benzaldehyde, 3,4-dihydroxybenzaldehyde and 4-hydroxy-3-methoxybenzaldehyde by pi ADH are from 9- to 29-fold higher than those for a class I isozyme, beta 1 gamma 2 ADH. Furthermore, the norepinephrine aldehydes are potent inhibitors of alcohol (ethanol) oxidation by pi ADH. The high catalytic activity of pi ADH-catalyzed reduction of the aldehydes in combination with a possible regulatory function of the aldehydes in the oxidative direction leads to essentially "unidirectional" catalysis by pi ADH. These features and the presence of pi ADH in human liver imply a physiological role for pi ADH in the degradation of circulating epinephrine and norepinephrine.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3466164      PMCID: PMC387042          DOI: 10.1073/pnas.83.23.8908

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  Double-ternary complex affinity chromatography: preparation of alcohol dehydrogenases.

Authors:  L G Lange; B L Vallee
Journal:  Biochemistry       Date:  1976-10-19       Impact factor: 3.162

2.  Some enzymic aspects of the production of oxidized or reduced metabolites of catecholamines and 5-hydroxytryptamine by brain tissues.

Authors:  R J Duncan; T L Sourkes
Journal:  J Neurochem       Date:  1974-05       Impact factor: 5.372

3.  Coupled oxidation-reduction activity of liver alcohol dehydrogenase.

Authors:  N K Gupta; W G Robinson
Journal:  Biochim Biophys Acta       Date:  1966-05-05

4.  Isolation and characterization of an anodic form of human liver alcohol dehydrogenase.

Authors:  W F Borson; T K Li
Journal:  Biochem Biophys Res Commun       Date:  1977-01-10       Impact factor: 3.575

5.  Human liver pi-alcohol dehydrogenase: kinetic and molecular properties.

Authors:  W F Bosron; T K Li; W P Dafeldecker; B L Vallee
Journal:  Biochemistry       Date:  1979-03-20       Impact factor: 3.162

6.  Enzymatic reduction of "biogenic" aldehydes in brain.

Authors:  B Tabakoff; R Anderson; S G Alivisatos
Journal:  Mol Pharmacol       Date:  1973-07       Impact factor: 4.436

7.  Human aldehyde dehydrogenase: kinetic identification of the isozyme for which biogenic aldehydes and acetaldehyde compete.

Authors:  A D MacKerell; E E Blatter; R Pietruszko
Journal:  Alcohol Clin Exp Res       Date:  1986-06       Impact factor: 3.455

8.  Reduction of biogenic aldehydes by aldehyde reductase and alcohol dehydrogenase from human liver.

Authors:  B Wermuth; J D Münch
Journal:  Biochem Pharmacol       Date:  1979-04-15       Impact factor: 5.858

9.  Isolation of pi-alcohol dehydrogenase of human liver: is it a determinant of alcoholism?

Authors:  T K Li; W F Bosron; W P Dafeldecker; L G Lange; B L Vallee
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

10.  Simulation of biogenic amine metabolism in the brain.

Authors:  A J Turner; J A Illingworth; K F Tipton
Journal:  Biochem J       Date:  1974-11       Impact factor: 3.857

View more
  8 in total

1.  Interaction between the functional polymorphisms of the alcohol-metabolism genes in protection against alcoholism.

Authors:  C C Chen; R B Lu; Y C Chen; M F Wang; Y C Chang; T K Li; S J Yin
Journal:  Am J Hum Genet       Date:  1999-09       Impact factor: 11.025

2.  Personality traits of agreeableness and extraversion are associated with ADH4 variation.

Authors:  Xingguang Luo; Henry R Kranzler; Lingjun Zuo; Shuang Wang; Joel Gelernter
Journal:  Biol Psychiatry       Date:  2006-10-25       Impact factor: 13.382

3.  Multiple ADH genes modulate risk for drug dependence in both African- and European-Americans.

Authors:  Xingguang Luo; Henry R Kranzler; Lingjun Zuo; Shuang Wang; Nicholas J Schork; Joel Gelernter
Journal:  Hum Mol Genet       Date:  2006-12-21       Impact factor: 6.150

4.  Ethanol at low concentrations protects glomerular podocytes through alcohol dehydrogenase and 20-HETE.

Authors:  Ellen T McCarthy; Jianping Zhou; Ryan Eckert; David Genochio; Rishi Sharma; Olurinde Oni; Alok De; Tarak Srivastava; Ram Sharma; Virginia J Savin; Mukut Sharma
Journal:  Prostaglandins Other Lipid Mediat       Date:  2014-11-04       Impact factor: 3.072

Review 5.  A new view of alcohol metabolism and alcoholism--role of the high-Km Class III alcohol dehydrogenase (ADH3).

Authors:  Takeshi Haseba; Youkichi Ohno
Journal:  Int J Environ Res Public Health       Date:  2010-03-15       Impact factor: 3.390

6.  Retinoic acid response element in the human alcohol dehydrogenase gene ADH3: implications for regulation of retinoic acid synthesis.

Authors:  G Duester; M L Shean; M S McBride; M J Stewart
Journal:  Mol Cell Biol       Date:  1991-03       Impact factor: 4.272

7.  Recessive genetic mode of an ADH4 variant in substance dependence in African-Americans: A model of utility of the HWD test.

Authors:  Xingguang Luo; Lingjun Zuo; Henry R Kranzler; Shuang Wang; Raymond F Anton; Joel Gelernter
Journal:  Behav Brain Funct       Date:  2008-09-18       Impact factor: 3.759

8.  The Pivotal Role of Aldehyde Toxicity in Autism Spectrum Disorder: The Therapeutic Potential of Micronutrient Supplementation.

Authors:  Frances Jurnak
Journal:  Nutr Metab Insights       Date:  2016-06-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.